echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Long-term use of metformin in high-risk diabetic patients is not related to cognitive decline

    Long-term use of metformin in high-risk diabetic patients is not related to cognitive decline

    • Last Update: 2017-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to a US study, long-term use of metformin in patients at high risk of diabetes was not associated with cognitive decline This finding adds confidence for clinicians and patients to use metformin for diabetes prevention Previous studies have shown that metformin use may be related to the deterioration of cognitive function and even the development of Alzheimer's disease, while other studies have shown that it can even improve memory According to the analysis of diabetes prevention outcomes in more than 2000 adults (http:// published online on May 12 in diabetes care, the use of metformin for more than 8 years will not lead to cognitive impairment The diabetes prevention study (DPP) was a placebo-controlled trial (http:// involving 3234 prediabetes individuals The study found that the incidence rate of type 2 diabetes decreased by 58% and 31% respectively in the intensive lifestyle intervention group and metformin group compared with placebo group After a 13-month transition period, participants continued to dppos The current situation analysis mainly focused on 2280 participants, including 749 in the lifestyle intervention group, 776 in the metformin group and 755 in the placebo group All participants completed the cognitive function assessment in the eighth year At the time of randomization, the average age of participants was 51.1 years old, 67.7% female and 54.6% white In the 8-year evaluation, the fasting blood glucose level, HbA1c area under the curve, and the prevalence and duration of type 2 diabetes in metformin and lifestyle intervention group were lower than those in placebo group In addition, there was no significant difference in the cognitive function of the three groups in the eighth year: lifestyle intervention group composite z-0.01, metformin group composite z-0.02, placebo group composite z-0.01 (P = 0.86) The results were independent of age and ApoE - ε 4 carrier status, which was considered a risk factor for cognitive impairment After adjusting for age, gender and race, the researchers also found no correlation between metformin exposure time and cognitive performance The researchers stressed that research on brain imaging changes will be carried out to further explore the correlation between metformin and brain changes.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.